Cost Effectiveness and Resource Allocation

Table 1 Morbidity risk of CHD and stroke and mortality risk (treated and untreated adults with GHD)

From: The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden

	Yearly morbidity risk				Yearly mortality risk
	CHD		Stroke		Mortality
	Treated	Untreated	Treated	Untreated	Treated	Untreated
Men, years
18–30	0	0	0	0	0	0.0145
31–54	0.0044	0.0045	0.0044	0.0038	0.0054	0.0179
55–65	0.0118	0.0281	0.0074	0.0144	0.0103	0.0406
65+	0.0185	0.0408	0.0123	0.0198	0.0559	0.0906
Women, years
18–30	0	0	0	0	0	0.0039
31–54	0.0022	0.0055	0.0011	0.0025	0.0045	0.0122
55–65	0.0045	0.0145	0.0067	0.0087	0.00159	0.0378
65+	0.0046	0.0306	0.0183	0.0164	0.0285	0.0673

CHD, coronary heart disease; GHD, growth hormone deficiency.
Sources of data: Swedish hospital discharge and causes of death registries (untreated); KIMS database (treated).

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com